Michelle P. Aranha, PhD1,2,3*, Romanos Sklavenitis-Pistofidis, MD1,2,3, Yoshinobu Konishi, MD, PhD1,2,3, Ting Wu, MS3*, Hong Yue, PhD4,5*, Elizabeth D. Lightbody, PhD1,2,3, Mahshid Rahmat, PhD1,2,3*, Michael Timonian, MD1,2,3*, Daniel L. Mallory, BS2,3*, Michael P. Agius, PhD1,2,3*, Shohreh Varmeh, PhD2*, Nang Kham Su, MSc2*, Jacqueline Perry, MPH2*, Erica M. Horowitz, BA2*, Maya Davis, BA2*, Anna Justis, PhD2*, Radosław P. Nowak, PhD4,5*, Mark Hamilton, PhD6*, Daniel Auclair, PhD6,7*, Catherine R. Marinac, PhD2, Eric Fischer, Ph.D.4,5*, Gad Getz, PhD3,8* and Irene M. Ghobrial, MD1,2,3
1Harvard Medical School, Boston, MA
2Dana-Farber Cancer Institute, Boston, MA
3Broad Institute of MIT and Harvard, Cambridge, MA
4Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA
5Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA
6Multiple Myeloma Research Foundation, Norwalk, CT
7Hematology R&D, AstraZeneca, Waltham, MA
8Department of Pathology, Massachusetts General Hospital Cancer Center, Boston, MA